Hetero Healthcare Limited, in strategic collaboration with Enzene Biosciences, has launched Perzea, India’s most affordable Pertuzumab biosimilar. The introduction of this targeted therapy for HER2-positive breast cancer demonstrates the synergy between two healthcare leaders committed to advanced cancer treatment accessibility.

Innovation Meets Affordability

Pertuzumab plays a vital role in the standard of care for HER2-positive breast cancer worldwide. By leveraging Enzene’s patented EnzeneX™ technology, Perzea becomes not only affordable but also reliable in terms of quality and production efficiency. This innovation-driven partnership sets new standards for biologics in India.